Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.

Journal of gastroenterology - 1 Jul 2001

Da Silva L C, Pinho J R, Sitnik R, Da Fonseca L E, Carrilho F J

Abstract excerpt

PURPOSE: A long-term follow-up study was carried out to evaluate the tolerability and efficacy of long-term therapy (1 to 3 years) with high doses (150 or 300 mg daily) of lamivudine for chronic hepatitis B. METHODS: Thirty-two patients were studied, including those who were seronegative for hepa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Drug Administration Schedule
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Interferon-alpha

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Share to Viremia

Source

Identifiers

PMID: 11480792
DOI: 10.1007/s005350170071

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-11480792-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.PMID 11480792Read ↗

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.Semantic proximity Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.Semantic proximity Read ↗

Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine.Semantic proximity Read ↗

Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.Semantic proximity Read ↗

Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.Semantic proximity Read ↗

HBV mutations associated with lamivudine therapy.Semantic proximity Read ↗

Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B.Semantic proximity Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.Semantic proximity Read ↗

Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.